Pathway-level targets

Pathway-level targets represent a conceptual framework in modern pharmacology where therapeutic intervention is directed at an entire biological signaling or metabolic network rather than a single molecular entity [1: Nature Reviews Drug Discovery]. This approach is particularly relevant in oncology and immunology, where cellular redundancy and feedback loops often render single-target inhibitors ineffective over time [2: NIH/PubMed]. By targeting multiple components or critical regulatory hubs within a pathway, such as the MAPK/ERK or PI3K/AKT/mTOR cascades, drug developers aim to achieve more robust clinical responses and circumvent resistance mechanisms [3: Science Signaling]. However, because biological pathways are highly interconnected, pathway-level targeting carries a significant risk of systemic toxicity and unintended consequences due to the disruption of homeostatic crosstalk [4: Science]. Success in this area typically requires the integration of systems biology, multi-omics data, and the development of sophisticated biomarkers to ensure precise patient stratification and monitoring [5: Journal of Molecular Medicine].

Other names

Network-based targetsSystems-level targetsPathway-centric drug discoveryMulti-node targeting

Simultaneous or sequential modulation of multiple nodes within a biological signaling or metabolic cascade to disrupt disease-driving networks.